Charles River Laboratories Intl. Inc vs Lucid Group Inc — how do they compare? Charles River Laboratories Intl. Inc trades at $302.17 (market cap $14.23B), while Lucid Group Inc trades at $3.79 (market cap $1.51B). The key difference: Charles River Laboratories Intl. Inc is far larger — about 9.4× Lucid Group Inc's market cap, and Charles River Laboratories Intl. Inc is trading nearer its 52-week high, Lucid Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Charles River Laboratories Intl. Inc for 33 Days and Lucid Group Inc for 45 Days on average.
| CRL | LCID | |
|---|---|---|
Market Cap | $14.23B | $1.51B |
Volume | 1,176,885 | 12,333,745 |
Sector | Health | Consumer Cyclical |
52-Week High | $310.77 | $21.92 |
52-Week Low | $149.93 | $3.82 |
Typical Hold Time | 33 Days | 45 Days |
Enterprise Value | $17.06B | $4.40B |
Signals from Pluang's Aura AI — not financial advice
CRL trades at $304.01, up 1.24% on the day, near the consensus price target of $305.50. The stock shows a bullish technical trend with strong analyst support (73% buy ratings) and has beaten EPS estimates for three consecutive quarters. However, fundamentals reveal challenges with negative net income margins and a high P/E ratio of 684.85, while recent news highlights a strategic growth plan targeting 5-7% revenue growth and $300 million in savings by 2030.
The outlook is cautiously optimistic given strong analyst sentiment and recent earnings beats, but high valuation and profitability concerns pose risks. Investment opportunity hinges on successful execution of the new growth strategy to improve margins, while key risks include persistent negative earnings, competitive pressures, and execution missteps in achieving long-term targets.
Lucid Group (LCID) trades at $3.785, down 2.7% with a bearish technical outlook. The company shows concerning fundamentals with negative profit margins (-249.21% net income margin) and consistent earnings misses. Recent news highlights operational challenges including delayed Cosmos SUV launch and aggressive cost-cutting targets of $1.4 billion for 2026. Cash flow remains negative at -$566 million, though strategic partnerships with Bolt for autonomous vehicles provide some growth potential.
LCID faces significant execution risks amid high cash burn and competitive EV market pressures. Analyst consensus is cautious with 67% hold ratings and $7.60 price target suggesting 101% upside potential. The stock presents high-risk speculation for investors betting on successful turnaround execution and partnership developments.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →Lucid Group Inc is a technology and automotive company. It develops the next generation of electric vehicle (EV) technologies. It is a vertically integrated company that designs, engineers, and builds electric vehicles, EV powertrains, and battery systems in-house using our own equipment and factory.
Read more on LCID →